TCGA-MT-A67A-01A-11R-A30B-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.510
- MYC_TARGETS_V2+0.500
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
- MYC_TARGETS_V1+0.270
- P53_PATHWAY+0.240
- DNA_REPAIR+0.230
- BILE_ACID_METABOLISM+0.180
- FATTY_ACID_METABOLISM+0.150
- ADIPOGENESIS+0.130
- PEROXISOME+0.120
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.570
- TGF_BETA_SIGNALING-0.490
- HEDGEHOG_SIGNALING-0.450
- MITOTIC_SPINDLE-0.450
- TNFA_SIGNALING_VIA_NFKB-0.430
- ANGIOGENESIS-0.400
- UV_RESPONSE_DN-0.400
- INFLAMMATORY_RESPONSE-0.380
- KRAS_SIGNALING_UP-0.370
- PROTEIN_SECRETION-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-GU-A763-01A-11R-A32O-07 | — | — | 0.934 |
| 2 | 9da01737-be8f-4af5-9f8f-47bb892b6339 | — | — | 0.881 |
| 3 | 4245e942-3439-4e98-9733-b0b8ac25ad56 | — | — | 0.862 |
| 4 | MDT-AP-1302 | Med | Medulloblastoma | 0.850 |
| 5 | TCGA-XF-AAN1-01A-31R-A42T-07 | — | — | 0.847 |
| 6 | fa9f3cc6-06eb-4cfd-8f85-9d13df39d11e | — | — | 0.845 |
| 7 | TCGA-KU-A6H7-06A-21R-A31N-07 | — | — | 0.844 |
| 8 | 79e77cb6-d567-4e9b-99df-e38e6e05d72e | — | — | 0.835 |
| 9 | SRR1313092 | — | B | 0.826 |
| 10 | TCGA-CV-A45Z-01A-21R-A24Z-07 | — | — | 0.817 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.510 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.270 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.240 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.090 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.060 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.060 | Cobimetinib | — uncovered |